Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Teclistamab or Talquetamab in Relapsed/Refractory Multiple Myeloma in China
ChiCTR2500112479Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of teclistamab and talquetamab in multiple myeloma (MM) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Overall response rate (ORR). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
teclistamabtalquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2500112479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112479.